Share This Page
Litigation Details for ABBVIE INC. v. HETERO USA INC. (D.N.J. 2026)
✉ Email this page to a colleague
ABBVIE INC. v. HETERO USA INC. (D.N.J. 2026)
| Docket | ⤷ Start Trial | Date Filed | 2026-01-07 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Jennifer Choe-Groves |
| Jury Demand | None | Referred To | Brendan Day |
| Patents | 12,090,148; 12,350,259; 12,383,545; 12,465,598 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ABBVIE INC. v. HETERO USA INC.
Details for ABBVIE INC. v. HETERO USA INC. (D.N.J. 2026)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2026-01-07 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: ABBVIE INC. v. HETERO USA INC. (D.N.J. 2026)
What is the litigation summary for AbbVie Inc. v. Hetero USA Inc., 3:26-cv-00114?
Executive summary
AbbVie Inc. v. Hetero USA Inc. (case no. 3:26-cv-00114) is a U.S. patent infringement dispute filed in 2026. The docket is in its early stage, so the case record is centered on pleadings and procedural motions rather than merits rulings. The actionable near-term question for generic/biosimilar strategy is whether Hetero has exposure to injunction and damages based on asserted Orange Book-listed patents tied to AbbVie’s branded product.
No specific asserted patent numbers, listed FDA product, or infringement allegations are provided in the input. Without the asserted-patent identifiers and the underlying FDA reference/product, a complete infringement-and-expiration analysis cannot be produced.
Which patents does AbbVie accuse Hetero of infringing in 3:26-cv-00114?
Answer (based on provided input): Not specified. The input includes only the case caption and docket number.
What to extract from the docket to identify the asserted estate
A litigation-ready patent map requires, at minimum:
- Asserted patent numbers (e.g., U.S. patents listed against the branded NDA under the Orange Book)
- Patent categories in suit (composition, formulation, method-of-use, manufacturing)
- Claim chart scope (which claims of which patents are asserted)
- Accused product description (strength/form, dosage form, and whether it is paragraph IV for a specific NDC)
Those items are not present in the input.
Is this a Hatch-Waxman Paragraph IV case, and what FDA approval triggers it?
Answer (based on provided input): Not specified.
How the triggering document typically appears
In Hatch-Waxman paragraph IV dockets, the complaint and related filings usually tie to:
- An ANDA filing by the generic applicant
- A paragraph IV certification against Orange Book patents
- A specific NDA/RLD and NDC-level strength and dosage form
No NDA/RLD linkage is included in the input.
What is the procedural posture of AbbVie v. Hetero (3:26-cv-00114)?
Answer (based on provided input): Not specified beyond docket existence.
What procedural markers determine timing and leverage
Early-stage leverage in these cases typically turns on:
- Whether the court entered a case schedule and claim construction timetable
- Whether there are motions to dismiss (jurisdiction, pleading sufficiency)
- Whether any preliminary injunction motion is pursued (rare in late Hatch-Waxman cycles, but sometimes used)
The input does not include docket events.
When is the next key milestone in 3:26-cv-00114 (claim construction, trial, or injunction)?
Answer (based on provided input): Not specified.
Milestones that drive business decisions
For infringement risk and settlement timing, the operative dates typically include:
- Markman/claim construction deadline(s)
- Expert disclosure and discovery cutoff
- Summary judgment deadlines
- Trial date (if set)
- Any injunction hearing date
Those dates are not provided.
How strong is AbbVie’s patent estate in this case?
Answer (based on provided input): Not specified.
What “strength” analysis depends on
Patent strength in these cases is driven by:
- Remaining term on asserted patents (expiration and any PTA/PTE impacts)
- Whether asserted claims are core (composition or method-of-use) versus peripheral (formulation/microstructure/manufacturing)
- Whether prior art and validity challenges are likely (anticipation/obviousness)
- Litigation history for the same family (enforcement pattern, outcomes)
None of this is available in the input.
What generic entry risks exist for Hetero under this litigation?
Answer (based on provided input): Not specified.
Risk framework used by brand owners and generics
The generic entry outcome depends on:
- Whether the case is stayed pending PTO/other proceedings
- Whether the generic approval is subject to 180-day exclusivity and whether the settlement affects launch
- Whether the court grants infringement + injunction or narrows to noninfringement/invalidity
No certification facts or asserted patent expiration windows are included.
What settlement terms are typical if AbbVie and Hetero resolve 3:26-cv-00114?
Answer (based on provided input): Not specified.
Typical settlement components (what to look for in filings)
When a Hatch-Waxman case settles, the deal often includes:
- A license with specified entry timing
- A carve-out tied to specific strengths/formulations
- Possible stipulated judgment of validity/infringement
- Payment and/or non-monetary consideration
- A “trigger” if the generic can launch earlier by design-around
The input does not include any settlement indication.
What is the Orange Book status of the AbbVie patents asserted against Hetero’s ANDA?
Answer (based on provided input): Not specified.
What the Orange Book analysis requires
To answer “Orange Book status,” the record must identify:
- The branded NDA
- The exact listed patents and their expiration dates
- Whether patents are labeled drug substance, drug product, or method of use
- Any pediatric exclusivity or other statutory exclusivities
No NDA, drug name, or patent list is provided.
Which companies are challenging the same AbbVie product family in parallel actions?
Answer (based on provided input): Not specified.
Why parallel actions matter
A crowded ANDA paragraph IV landscape changes:
- The practical value of a settlement with one applicant
- Risk of multiple injunction threats
- Predictive value for claim construction and validity outcomes
No parallel docket or competitor list is in the input.
Manufacturing and formulation design-around: does AbbVie’s complaint target a specific dosage form?
Answer (based on provided input): Not specified.
Design-around depends on claim type
- Composition/formulation claims usually narrow to specific chemical structures and formulation parameters
- Method-of-use claims target clinical regimen and indication-specific labeling
- Manufacturing claims target process steps or intermediates
No claim or accused product details are included.
Key Takeaways
- The input identifies the dispute as AbbVie Inc. v. Hetero USA Inc., 3:26-cv-00114, but provides no asserted patent list, no FDA product linkage, and no docket events.
- A litigation summary that supports business decisions (validity/injunction exposure, settlement dynamics, launch timing) requires those identifiers, which are not included.
FAQs
- What does case number 3:26-cv-00114 indicate about venue and procedural rules in the AbbVie v. Hetero dispute?
- How do asserted Orange Book patents usually map to claim types in AbbVie Hatch-Waxman suits?
- What court-ordered deadlines in Hatch-Waxman dockets typically determine settlement pressure?
- How does 180-day exclusivity affect a generic launch during ongoing AbbVie v. Hetero litigation?
- What design-around strategies are commonly used when a method-of-use claim drives the infringement theory?
References
No sources were cited because the input did not provide any docket text, asserted patents, FDA product, or filing documents to support citation.
More… ↓
